TP53, PIK3CA, FBXW7 and KRAS Mutations in Esophageal Cancer Identified by Targeted Sequencing.
OBJECTIVE
Esophageal cancer (EC) is a common malignancy with significant morbidity and mortality. As individual cancers exhibit unique mutation patterns, identifying and characterizing gene mutations in EC that may serve as biomarkers might help predict patient outcome and guide treatment. Traditionally, personalized cancer DNA sequencing was impractical and expensive. Recent technological advancements have made targeted DNA sequencing more cost- and time-effective with reliable results. This technology may be useful for clinicians to direct patient treatment.


METHODS
The Ion PGM and AmpliSeq Cancer Panel was used to identify mutations at 737 hotspot loci of 45 cancer-related genes in 64 EC samples from Chinese patients.


RESULTS
Frequent mutations were found in TP53 and less frequent mutations in PIK3CA, FBXW7 and KRAS.


CONCLUSIONS
These results demonstrate that targeted sequencing can reliably identify mutations in individual tumors that make this technology a possibility for clinical use.
The First Hospital of Qiqihar, Qiqihar, P.R. China.
Huili
H
Zheng
The First Hospital of Qiqihar, Qiqihar, P.R. China wy2459691@163.com siyichen@usc.edu.
Yan
Y
Wang
San Valley Biotechnology Inc., Beijing, P.R. China.
Chuanning
C
Tang
Norris Comprehensive Cancer Center, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA, U.S.A.
Lindsey
L
Jones
San Valley Biotechnology Inc., Beijing, P.R. China.
Hua
H
Ye
San Valley Biotechnology Inc., Beijing, P.R. China.
Guangchun
G
Zhang
The First Hospital of Qiqihar, Qiqihar, P.R. China.
Weihai
W
Cao
The First Hospital of Qiqihar, Qiqihar, P.R. China.
Jingwen
J
Li
The First Hospital of Qiqihar, Qiqihar, P.R. China.
Lifeng
L
Liu
The First Hospital of Qiqihar, Qiqihar, P.R. China.
Zhencong
Z
Liu
The First Hospital of Qiqihar, Qiqihar, P.R. China.
Chao
C
Zhang
San Valley Biotechnology Inc., Beijing, P.R. China.
Feng
F
Lou
San Valley Biotechnology Inc., Beijing, P.R. China.
Zhiyuan
Z
Liu
San Valley Biotechnology Inc., Beijing, P.R. China.
Yangyang
Y
Li
San Valley Biotechnology Inc., Beijing, P.R. China.
Zhenfen
Z
Shi
San Valley Biotechnology Inc., Beijing, P.R. China.
Jingbo
J
Zhang
San Valley Biotechnology Inc., Beijing, P.R. China.
Dandan
D
Zhang
San Valley Biotechnology Inc., Beijing, P.R. China.
Hong
H
Sun
San Valley Biotechnology Inc., Beijing, P.R. China.
Haichao
H
Dong
San Valley Biotechnology Inc., Beijing, P.R. China.
Zhishou
Z
Dong
San Valley Biotechnology Inc., Beijing, P.R. China.
Baishuai
B
Guo
San Valley Biotechnology Inc., Beijing, P.R. China.
H E
HE
Yan
San Valley Biotechnology Inc., Beijing, P.R. China.
Qingyu
Q
Lu
Norris Comprehensive Cancer Center, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA, U.S.A.
Xue
X
Huang
Norris Comprehensive Cancer Center, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA, U.S.A. wy2459691@163.com siyichen@usc.edu.
Si-Yi
SY
Chen
D000368:Aged; D000369:Aged, 80 and over; D018797:Cell Cycle Proteins / Q000235:genetics*; D058534:Class I Phosphatidylinositol 3-Kinases; D019295:Computational Biology; D030541:Databases, Genetic; D004938:Esophageal Neoplasms / Q000235:genetics* / Q000473:pathology; D044783:F-Box Proteins / Q000235:genetics*; D000073979:F-Box-WD Repeat-Containing Protein 7; D005260:Female; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D060787:Neoplasm Grading; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics*; D015203:Reproducibility of Results; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*; D044767:Ubiquitin-Protein Ligases / Q000235:genetics*
D018797:Cell Cycle Proteins; D044783:F-Box Proteins; D000073979:F-Box-WD Repeat-Containing Protein 7; C513273:FBXW7 protein, human; C117307:KRAS protein, human; D016159:Tumor Suppressor Protein p53; D044767:Ubiquitin-Protein Ligases; D019869:Phosphatidylinositol 3-Kinases; D058534:Class I Phosphatidylinositol 3-Kinases; C484760:PIK3CA protein, human; D016283:Proto-Oncogene Proteins p21(ras)
Esophageal cancer; Ion PGM; genetic mutations; next-generation sequencing; personalized medicine; targeted therapy